Demographic data of the study cohort
| Patient characteristics | Whole cohort (n=920) | Pneumococcal cohort (n=366) |
| Demographics | ||
| Age, median; years (IQR) | 71.7 (57.8–80.8) | 71.1 (52.9–80.7) |
| Male (%) | 546 (59.3) | 193 (52.7) |
| Residential or nursing care home resident (%) | 51 (5.5) | 25 (6.8) |
| WHO performance status ≥2 (%) | 138 (15.0) | 62 (16.9) |
| COPD (%) | 244 (26.5) | 94 (25.7) |
| Ischaemic heart disease (%) | 145 (15.8) | 61 (16.7) |
| Diabetes mellitus (%) | 130 (14.1) | 54 (14.8) |
| Cerebrovascular disease (%) | 103 (11.2) | 45 (12.3) |
| Asthma (%) | 102 (11.1) | 47 (12.8) |
| Congestive cardiac failure (%) | 74 (8.0) | 26 (7.1) |
| Active malignancy (%) | 67 (7.3) | 38 (10.4) |
| Dementia (%) | 32 (3.5) | 21 (5.7) |
| Mean Charlson co-morbidity index (95% CI) | 1.48 (1.37 to 1.59) | 1.58 (1.40 to 1.76) |
| Influenza vaccination in preceding 12 months (%) | 558/855 (65.3) | 219/334 (65.6) |
| PPV in preceding 10 years (%) | 383/824 (46.5) | 147/320 (45.9) |
| Severity | ||
| PSI class I–III (%) | 395 (42.9) | 151 (41.2) |
| PSI class IV (%) | 336 (36.5) | 132 (36.1) |
| PSI class V (%) | 189 (20.5) | 83 (22.7) |
| CURB-65 0–1 (%) | 393 (42.7) | 143 (39.1) |
| CURB-65 2 (%) | 320 (34.8) | 127 (34.7) |
| CURB-65 3–5 (%) | 207 (22.5) | 96 (26.2) |
| Outcome | ||
| 30-day mortality (%) | 92 (10.0) | 35 (9.6) |
| LOS | 7 (4–12) | 8 (4–13) |
| IRVS (%) | 82 (8.9) | 43 (11.7) |
COPD, chronic obstructive pulmonary disease; IRVS, invasive respiratory or vasopressor support; LOS, length of (hospital) stay; PPV, pneumococcal polysaccharide vaccine; PSI, pneumonia severity index.